Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

vents was 9.3% in the Albuferon 900 Q2w treatment group, vs. 6.1% in the Pegasys group.

"The 900-mcg Albuferon dose has the potential to offer patients an attractive therapeutic option, requiring half as many injections as Pegasys, with more favorable quality of life effects and favorable sustained virologic response data," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS.

    Albuferon 1200-mcg Every Two Weeks (Albuferon 1200 Q2w)


    -- ITT analysis shows that 55.5% of patients in the Albuferon 1200 Q2w

       treatment group achieved SVR, vs. 57.9% for Pegasys administered every

       week.

    -- In heavier patients (>75 kg) who were treatment-adherent, 67.9% of

       those in the Albuferon 1200 Q2w treatment group achieved SVR, versus

       53.3% for Pegasys every week.

    -- Among all treatment-adherent patients in the Albuferon 1200 Q2w

       treatment group, 70.6% achieved SVR, versus 66.7% for Pegasys.

    -- ITT analysis shows that the Albuferon 1200 Q2w treatment group

       exhibited a robust early antiviral response (reduction in hepatitis C

       RNA viral load to below the level of quantitation):  74.5% for

       Albuferon 1200 Q2w at Week 12, vs. 65.8% for Pegasys.  The Albuferon

       1200 Q2w treatment group also had the most rapid time to HCV RNA

       negativity.

    -- The rate of discontinuations due to adverse events was 18.2% in the

       Albuferon 1200 Q2w treatment group, vs. 6.1% in the Pegasys group.

       Adverse events observed were those typically expected with interferon

       therapy.  Dose reductions were attempted in only 30.0% of Albuferon

       subjects prior to discontinuation, versus 42.9% for Pegasys.

"In the Albuferon Phase 3 trials, we will strongly encourage titration of dose where necessary to ensure tolerability, reduce the rate of discontinuations, and maximize the therapeutic benefit of the robust early antiviral
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Calif., March 20 Poniard Pharmaceuticals, Inc. (Nasdaq: ... on oncology, today announced that it will concentrate ... development of its late-stage oncology candidate, picoplatin. As ... preclinical research operations and reduced its workforce by ...
... Qutenza(TM) Receives Positive Committee Recommendation in European ... approval of Qutenza(TM) (formerly NGX-4010) for treatment ... either alone or in combination with other ... for review by U.S. FDA for PHNUpcoming ...
... March 20 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... for the live conference call held on March 19, 2009 ... March 19, 2009 at 7:30 PM ET to March 26, ... 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). To listen to the ...
... A campaign which will reduce mortality in patients with ... coalition which includes the ESC Working Group on Acute ... Interventions (EAPCI). "Stent 4 Life" is a project designed ... percutaneous coronary interventions (PCI, with balloon angioplasty and stent) ...
... leading private equity investment fund ("JLL"), and PharmaNet Development ... (Nasdaq: PDGI ) ("PharmaNet"), today announced the ... Holdings, LLC ("Parent"), through its wholly-owned subsidiary, PDGI Acquisition ... common stock of PharmaNet. Parent and Purchaser are ...
... to work, maybe you can walk at work ... 3 is National Walk to Work Day. ... Human Services, the sixth-annual event encourages Americans to ... http://www.newscom.com/cgi-bin/prnh/20090320/DE86407 )The reason is clear: According to ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 2Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11Health News:Nuvilex Provides Conference Call Replay Information 2Health News:'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 3Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 4Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 5Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 6Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 7Health News:National Walk to Work Day is April 3 2Health News:National Walk to Work Day is April 3 3
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is a reagent and probe system used ... high throughput plate based system is a ... a unique approach for RNA detection and ... branched DNA (bDNA) technology. Branched DNA allows ...
Medicine Products: